Adults 21 to 65, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Efficacy by UHDRS-TMSPrimary· monthly for eleven months
The primary endpoint was the rate of change (slope) in Unified Huntington's Disease Rating Scale - Total Motor Score from V0 to V11 (minimum 0, the best; and maximum 124, the worst). For each participant, a regression line was fitted (Y = a + bx), where b represents the individual slope, reflecting the annualised rate of motor progression. A negative slope suggests improvement or slower decline; a positive slope indicates worsening. To compare treatment efficacy, the slopes were analysed using a Mixed Model for Repeated Measures (MMRM), which accounts for intra-subject variability and missing
Group
Value
95% CI
Nestacell (Former Cellavita HD) Lower Dose
-1.23
± 0.84
Nestacell (Former Cellavita HD) Higher Dose
0.84
± 0.90
Placebo Group
8.91
± 1.11
Efficacy by UHDRS-TFCSecondary· monthly for eleven months
Assessed by the rate of change (slope) from V0 to V11 in the UHDRS-TFC.
The response of each participant or means of all participants was evaluated by the slopes of each regression line of UHDRS-TFC determined as follows:
The equation describes the regression line: Y = a + bx, where:
* "Y" is the dependent variable.
* "a" is the constant that represents the intersection of the line with the vertical axis.
* "b" is the angular coefficient, that is, the slope.
* "x" is the independent variable. Therefore, the 'b' value represents the slope of the straight line that best fits the values collec
Group
Value
95% CI
Nestacell (Former Cellavita HD) Lower Dose
-0.29
± 0.18
Nestacell (Former Cellavita HD) Higher Dose
0.73
± 0.18
Placebo Group
-0.89
± 0.26
Exposure to NestaCell (Former Cellavita HD) ProductSecondary· eleven months
Number of administrations of NestaCell (Former Cellavita HD) and Placebo
Group
Value
95% CI
Nestacell (Former Cellavita HD) Lower Dose
9.0
± 0.0
Nestacell (Former Cellavita HD) Higher Dose
8.4
± 1.5
Placebo Group
9.0
± 0.0
Adverse events — posted to ClinicalTrials.gov
Time frame: 11 months.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a prospective, phase II, single-center, randomized (2:2:1), triple-blind, placebo controlled study, with two test doses of Cellavita HD product.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
· Phase 3
· recruiting
NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease
· recruiting
NCT06774443 — Hinting Task for Huntington's Disease
· recruiting
NCT06546488 — Cognitive Assessment Tools for Huntington's Disease.
· recruiting
NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease
· recruiting
Other Azidus Brasil trials
Trials by the same sponsor.
NCT06303635 — Safety of UFRJvac, Trivalent COVID-19 Vaccine
· unknown
NCT06097780 — Efficacy and Safety of NestaCell® in Huntington's Disease
· Phase 3
· unknown
NCT06150833 — Efficacy and Safety and Pharmacokinetics of Boya IVIG
· Phase 3
· unknown
NCT05603403 — Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms
· Phase 4
· completed
NCT05009277 — Study To Evaluate The Sensitivity Of The Linda Thermal Device
· unknown
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azidus Brasil
Last refreshed: 19 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03252535.